Law360 Names Four Partners “Rising Stars”
Law360 named four Ropes & Gray attorneys to its 2023 “Rising Stars” list:
- health care partners Christina Bergeron and Jennifer Romig were recognized as Health Care Rising Stars
- business restructuring partner Cristine Pirro Schwarzman was recognized as a Bankruptcy Rising Star
- mergers & acquisitions partner Suni Sreepada was recognized as a Life Sciences Rising Star
About our winners:
Christina Bergeron and Jennifer Romig kicked off 2023 by closing one of the most significant health care deals of the year, Amazon’s purchase of One Medical. Jennifer and Christina represented 1Life Healthcare, Inc. (One Medical), a leading national technology-powered primary care organization, in its all-cash sale to e-commerce giant Amazon, Inc., for $18 per share, or approximately $3.9 billion. Jennifer and Christina co-led the transaction with respect to healthcare matters including regulatory strategy on multiple deal points, such as healthcare and privacy related considerations for the filing with the Federal Trade Commission. Their guidance was critical to the transaction being a successful one, and Jennifer and Christina have continued to counsel One Medical through the integration with Amazon.
Cristine Pirro Schwarzman is currently co-leading FORMA Brands in the chapter 11 cases of FB Debt Financing Guarantor, LLC and certain of its subsidiaries (“Forma Brands”), a builder of top beauty brands including Morphe®, Morphe 2®, Jaclyn Cosmetics®, and Born Dreamer®, in their Chapter 11 cases, to address approximately $870 million of funded indebtedness. In addition, Cristine she helped FORMA Brands in securing approximately $33 million in debtor-in-possession financing, which enabled the client to support the business and its operations throughout the court-supervised sale process.
Suni Sreepada represented Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, in its $2.9 billion acquisition by Sanofi, the most recent in a series of high profile transactions that also includes 2022’s acquisition of Zymergen Inc. by Ginkgo Bioworks.